|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00129129 |
This study is evaluating the safety and immunogenicity of GSK Biologicals' Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, each administered at 2, 4, and 6 months of age, and compared to licensed meningococcal serogroups A, C, Y, and W-135 polysaccharide vaccine administered at 3 to 5 years of age.
The safety and immunogenicity of a booster dose of Hib-MenCY-TT vaccine will be compared to a booster dose of licensed Hib conjugate vaccine, each administered at 12 to 15 months of age. The group primed with the Hib conjugate vaccine will re-randomized at 12-15 months of age to receive a booster dose of Hib-MenCY-TT or a booster dose of the Hib conjugate vaccine.
Condition | Intervention | Phase |
Meningococcal Infections Haemophilus Influenzae Type b Infections |
Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine Biological: ActHIB Biological: Pediarix Biological: Prevnar Biological: Menomune |
Phase II |
MedlinePlus related topics: | Flu Tetanus Whooping Cough |
ChemIDplus related topics: | Tetanus Vaccine Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines Meningococcal Vaccines |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Subject), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Y |
Enrollment: | 759 |
Study Start Date: | August 2004 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Group A (Primary & Booster phases): Experimental |
Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Primary phase: 3 IM doses Booster phase: 1 IM dose
Biological: Pediarix
Primary phase: 3 IM doses
Biological: Prevnar
Primary phase: 3 IM doses Booster phase: 1 IM dose
|
Group B (Primary phase): Active Comparator |
Biological: ActHIB
Primary phase: 3 IM doses Booster phase: 1 IM dose
Biological: Pediarix
Primary phase: 3 IM doses
Biological: Prevnar
Primary phase: 3 IM doses Booster phase: 1 IM dose
|
Group C (Primary phase): Active Comparator |
Biological: Menomune
Primary phase: 1 SC dose
|
Group D (Booster phase): Active Comparator
Subjects from the Group B in the primary phase are randomized to either Group D or Group E in the booster phase
|
Biological: ActHIB
Primary phase: 3 IM doses Booster phase: 1 IM dose
Biological: Prevnar
Primary phase: 3 IM doses Booster phase: 1 IM dose
|
Group E (Booster phase): Experimental
Subjects from the Group B in the primary phase are randomized to either Group D or Group E in the booster phase.
|
Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine
Primary phase: 3 IM doses Booster phase: 1 IM dose
Biological: Prevnar
Primary phase: 3 IM doses Booster phase: 1 IM dose
|
The non-inferiority of the immunogenicity, safety, and antibody persistence of Hib-MenCY-TT vaccine will be compared to ActHIB®, a monovalent Hib conjugate vaccine licensed in the US.
All subjects will be vaccinated at 2, 4, 6, and 12 to 15 months. The immunogenicity of the MenC and MenY antigens will be summarized.
MenC and MenY immunogenicity will be compared to Menomune® (a quadrivalent meningococcal A, C, Y, and W-135 plain polysaccharide vaccine licensed in the US) administered to children 3 to 5 years of age.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Ages Eligible for Study: | 6 Weeks to 15 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
For Groups A and B
For Group C
Exclusion Criteria:
-For Groups A and B
For Group C
United States, Louisiana | |||||
GSK Clinical Trials Call Center | |||||
Bossier City, Louisiana, United States | |||||
United States, Massachusetts | |||||
GSK Clinical Trials Call Center | |||||
Boston, Massachusetts, United States |
GlaxoSmithKline |
Study Director: | Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Isabelle Harpigny ) |
Study ID Numbers: | 101858, 102015 |
First Received: | August 10, 2005 |
Last Updated: | September 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00129129 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|